Korean J Gastroenterol.  2020 May;75(5):308-310. 10.4166/kjg.2020.75.5.308.

Persistence of Hepatocellular Carcinoma Risk after Hepatitis C Virus Eradication

• Han S
• Park JY

• KMID: 2504252
• DOI: http://doi.org/10.4166/kjg.2020.75.5.308

Reference

1. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. 2017; Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 166:637–648. DOI: 10.7326/M16-2575. PMID: 28319996. PMCID: PMC5486987.

2. Terrault NA, Zeuzem S, Di Bisceglie AM, et al. 2016; Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 151:1131–1140.e5. DOI: 10.1053/j.gastro.2016.08.004. PMID: 27565882. PMCID: PMC5300778.

3. Calvaruso V, Cabibbo G, Cacciola I, et al. 2018; Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology. 155:411–421.e4. DOI: 10.1053/j.gastro.2018.04.008. PMID: 29655836.

4. Innes H, Barclay ST, Hayes PC, et al. 2018; The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen. J Hepatol. 68:646–654. DOI: 10.1016/j.jhep.2017.10.033. PMID: 29155019.

5. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. 2017; Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 153:996–1005.e1. DOI: 10.1053/j.gastro.2017.06.012. PMID: 28642197.

6. Romano A, Angeli P, Piovesan S, et al. 2018; Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study. J Hepatol. 69:345–352. DOI: 10.1016/j.jhep.2018.03.009. PMID: 29551707.

7. Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. 2020; Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatology. 71:44–55. DOI: 10.1002/hep.30823. PMID: 31222774.

8. Chou R, Wasson N. 2013; Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 158:807–820. DOI: 10.7326/0003-4819-158-11-201306040-00005. PMID: 23732714.

9. Lu M, Li J, Zhang T, et al. 2016; Serum biomarkers indicate long-term reduction in liver fibrosis in patients with sustained virological response to treatment for HCV infection. Clin Gastroenterol Hepatol. 14:1044–1055.e3. DOI: 10.1016/j.cgh.2016.01.009. PMID: 26804385. PMCID: PMC5726250.

10. Conti F, Buonfiglioli F, Scuteri A, et al. 2016; Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 65:727–733. DOI: 10.1016/j.jhep.2016.06.015. PMID: 27349488.

11. Su F, Ioannou GN. 2019; Hepatocellular carcinoma risk after direct-acting antiviral therapy. Clin Liver Dis (Hoboken). 13:6–12. DOI: 10.1002/cld.781. PMID: 31168359. PMCID: PMC6465785.

12. Carrat F, Fontaine H, Dorival C, et al. 2019; Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 393:1453–1464. DOI: 10.1016/S0140-6736(18)32111-1. PMID: 30765123.